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A B S T R A C T
Multiple system atrophy (MSA) is sporadic, progressive neurodegenerative disorder characterized clinically by auto-
nomic dysfunction, Parkinsonism (MSA-P), and cerebellar ataxia (MSA-C) in any combination. Parkinsonism is present
in the majority of patients (80%). Early in the course of the disease autonomic dysfunctions are present in approximately
40% of patients, while the domination of cerebellar symptoms is present in 20% of all patients1,2. According to second con-
sensus statement on diagnosis of MSA, to make the diagnosis of possible MSA, except Parkinsonism or a cerebellar syn-
drome, there must be one feature involving autonomic dysfunction plus one other additional that can include findings on
history, clinical examination or changes in structural or functional imaging3. We present a case of 60-year old male with
Parkinsonism and cerebellar symptoms accompanied with signs of autonomic nervous system involvment. Level of auto-
nomic dysfunction was not the level required for the diagnosis of probable MSA. On initially performed 1.5T MRI, the
most prominent neurodegenerative feature of brain stem, cerebellum and basal ganglia was atrophy, however features
like »hot-cross bun« sign, »slit-like« putaminal rim and middle cerebellar peduncle hyperintensities were detected only
after MR imaging on higher resolution (3T) device4. Our case points to the possibility that some typical structural
changes that can help in diagnostic process may not be clearly visible on 1.5 T MRI devices. In such cases we suggest us-
ing 3T MRI device, if feasible, in order to demonstrate findings that may help in establishing the diagnosis of possible
MSA.
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Introduction
Multiple system atrophy (MSA) is a sporadic, adult-
-onset and progressive neurodegenerative disease of un-
determined etiology, characterized with combination of
Parkinsonism (MSA-P), cerebellar ataxia (MSA-C) and
autonomic dysfunction (MSA-A)1,2. Symptoms of MSA
vary in distribution, onset and severity. Early in the
course of the disease autonomic dysfunction is present in
approximately 40% of patients and later it is present in
almost all patients. Parkinsonism is present in the ma-
jority of all patients (80%), while the domination of cere-
bellar symptoms is present in 20% of all patients1,2. Cell
loss, gliosis, and glial cytoplasmatic inclusions (GCIs) are
the typical pathologic features that can be found in sev-
eral brain and spinal cord structures. In MSA-P the
neurodegeneration is most prominent in the nigrostria-
tal system, while in MSA-C it is more expressed in the
olivopontocerebellar system. Autonomic system involve-
ment is related to cell loss in the dorsal motor nucleus of
the vagus nerve, the locus coeruleus, and the ventrola-
teral medulla, as well as parasympathetic preganglionic
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nuclei in the spinal cord1. The pathologic hallmark of
MSA is the presence of cytoplasmatic inclusion bodies in
glial cells (GCIs) of the basal ganglia, supplementary and
primary motor cortices, reticular formation, and pon-
tocerebellar system. These inclusions called Papp-Lantos
inclusions contain ubiquitin, tau, and fibrillized alpha-
-synuclein proteins and are definitive for the diagnosis of
MSA1,5,6. The prevalence of MSA is higher in male than
female patients (approximately 1.3:1). The symptoms
typically begin in the 6th decade of life, with approxi-
mately 6–9 years survival after the establishing the diag-
nosis. It is a relatively rare disorder, with annual inci-
dence of 3 new cases per 100,000 people. Until now, there
is no strong evidence supporting genetic nature of MSA7.
In order to uniform the diagnostic process, consensus
conference on the diagnosis of MSA was held in 1998. Ac-
cording to these criteria, there were two categories of
MSA: MSA with predominant cerebellar ataxia (MSA-C)
and MSA with predominant Parkinsonism (MSA-P).
Three levels of certainty were established, possible, prob-
able, and definite MSA8. Many following studies demon-
strated high predictive accuracy but low level of sensitiv-
ity of these criteria9,10. Practical implementation of these
criteria was sometimes very difficult and complicated.
Due to additional information relevant to diagnostic cri-
teria that occurred from following clinical and laboratory
studies11, biochemical and neuropathologic findings12,
and neuroimaging studies13,14, new (second) consensus
conference was held in order to create new guidelines,
with higher accuracy and much more practical use in di-
agnostic process of MSA3. According to the second con-
sensus criteria, the diagnosis of MSA should be divided
into three groups;
1. Definite MSA requires the neuropathologic find-
ings of widespread CNS a-synuclein–positive GCIs
and neurodegenerative changes in nigrostriatal or
olivopontocerebellar structure15,
2. Probable MSA – criteria listed in Table 1,
3. Possible MSA – criteria listed in Tables 2 and 3.
The definition of the disease onset include first sign of
any motor problem, whether parkinsonian or cerebellar,
or autonomic features, that are listed in Table 2. The
male erectile dysfunction (ED) is excluded3.
Autonomic dysfunction
At the onset of the disease, autonomic failure is pres-
ent in about 40% of patients, with impotence as the most
frequent initial symptom in males16, while in females it
was the urinary incontinence. Fecal incontinence and
constipation affects about 30% of patients. Criteria for
autonomic failure are listed in Table 1. Orthostatic hypo-
tension is present in about 60% of patients. The clinical
diagnosis of probable MSA requires a reduction of sys-
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TABLE 1
CRITERIA FOR PROBABLE MULTIPLE SYSTEM ATROPHY
A sporadic, progressive, adult (>30 years) onset disease char-
acterized by
• Autonomic failure involving urinary incontinence (inability
to control the release of urine from bladder with erectile dys-
function in male) decrease of blood pressure within 3 min of
standing by at least 30 mm Hg systolic or 15 mm Hg diastolic
and
• Poorly levodopa-responsive parkinsonism (bradikynesia with
rigidity, tremor or postural instability) or
• A cerebellar syndrome (gait ataxia with cerebellar dysarthria,
limb ataxia, or cerebellar oculomotor dysfunction)
TABLE 2
CRITERIA FOR POSSIBLE MULTIPLE SYSTEM ATROPHY
A sporadic, progressive, adult (>30 years) onset disease char-
acterized by
• Parkinsonism (bradikynesia with rigidity, tremor or postural
instability) or
• A cerebellar syndrome (gait ataxia with cerebellar dysarthria,
limb ataxia, or cerebellar oculomotor dysfunction) and
• At least one feature suggesting autonomic dysfunction (oth-
erwise unexplained urinary urgency, frequency or incomplete
bladder emptying, erectile dysfunction in male, or significant
orthostatic blood pressure decline that does not meet the
level required in probable MSA) and
• At least one of the additional features listed in Table 3.
MSA – multiple system atrophy
TABLE 3
ADDITIONAL FEATURES OF POSSIBLE MULTIPLE SYSTEM
ATROPHY
Possible MSA-P or MSA-C
• Babinski sign with hyperreflexia
• Stridor
Possible MSA-P
• Rapidly progressive parkinsonism
• Poor response to levodopa
• Postural instability within 3 years of motor onset
• Gait ataxia, cerebellar dysarthria, limb ataxia or cerebellar
oculomotor dysfunction
• Dysphagia within 5 years of motor onset
• Atrophy on MR of putamen, middle cerebellar peduncles, pons
or cerebellum
• Hypometabolism on FDG-PET in putamen, brainstem or cer-
ebellum
Possible MSA-C
• Parkinsonism (bradykinesia and rigidity)
• Atrophy onMR of putamen, middle cerebellar peduncles, pons
• Hypometabolism on FDG-PET in putamen
• Presynaptic nigrostriatal dopaminergic denervation on SPECT
or PET
MR – magnetic resonance, MSA-P – multiple system atrophy with
predominant Parkinsonism, MSA-C – multiple system atrophy
with predominant cerebellar ataxia, FDG (18F) – fluorodeoxyglu-
cose, FDG-PET – positron emission tomography with fluorode-
oxyglucose, PET – positron emission tomography, SPECT – sin-
gle photon emission computerized tomography
tolic blood pressure by at least 30 mmHg, or reduction of
diastolic blood pressure by at least 15 mm Hg after 3
minutes of standing; (previously, the patient had to spend
3-minute in the recumbent position). Usually, during this
orthostatic blood pressure decrease, compensatory in-
crease of the heart rate is to low for the level of blood
pressure decline. Other disorders which may cause or-
thostatic hypotension, like diabetic autonomic neuropa-
thy and drug induced hypotension should be excluded.
Parkinsonism
Parkinsonism, with different level of akinesia and ri-
gidity is present in most patients with MSA. The tremor
is usually asymmetric, postural and related to action.
The response to chronic levodopa therapy is usually poor,
although initially 30% of patients may show some, but
usually waning response17. Escalating doses of levodopa
with a peripheral decarboxylase inhibitor over 3 months
up to at least 1 g/d should be used to test the response. A
positive response is characterized with clinically signifi-
cant motor improvement like an improvement of 30% or
more on part III of the UPDRS or on part II of the
Unified Multiple System Atrophy Rating Scale18.
Cerebellar syndrome
Gait ataxia is the most common cerebellar symptom
and is often accompanied by cerebellar dysarthria (ataxia
of speech) and oculomotor dysfunction of cerebellar origin.
Other symptoms that occur frequently in MSA in-
clude dysphagia, sleep disorders, obstructive sleep apnea,
memory impairment, vivid dreams and confusion. Ac-
cording to Second criteria, new powerful tools in estab-
lishing the diagnosis are some structural and functional
imaging methods: positron emission tomography with
fluorodeoxyglucose (FDG-PET), singe photon emission
computerized tomography (SPECT) and magnetic reso-
nance imaging (MRI).
In both MSA-P and MSA-C, typical MRI atrophic
changes are visible in putamen, pons and middle cerebel-
lar peduncle (MCP)19. The recent (second) criteria opera-
te standard with 1.5-Tesla MRI and T2 weighted images,
that demonstrate changes in the basal ganglia (posterior
putaminal hypointensity and hyperintense lateral pu-
taminal rim) and brainstem (hot cross bun sign and MCP
hyperintensities)3.
FDG-PET demonstration of hypometabolism in stria-
tum and brainstem can also help in diagnosis of MSA20.
Case Report
We present a case of 60-year old male with onset of
symptoms six months prior to his first neurological exam.
Initially, he complained about clumsiness and stiffness,
gait unsteadiness, speech disturbance and change in
handwriting. He also reported erectile dysfunction and
feeling of dizziness after standing up from the sitting po-
sition. Later, he started to use artificial tears due to dry
eyes. There was no family history of similar illness. On
the neurologic exam he had hypomimia, with a reduced
blink rate. The speech was disarthric. There was cog-
wheel rigidity of right > left upper extremity, tone of the
right extremities was increased. Intention tremor, dyssy-
nergia and dysmetria, and dysdiadokinesia were noted.
There was reduction in speed and amplitude during re-
petitive actions of right extremities. The muscle stretch
reflexes were brisk and plantar response was flexor. The
gait was broad-based, with variable stride length and
swaying. After 3 minutes of standing we measured a
blood pressure falling by 20 mmHg systolic and 15 mm
Hg diastolic. Time and frequency domain 24 hours heart
rate variability as well as tilt table test showed no clini-
cally relevant autonomic disorder. Schirmer test showed
decreased basal secretion of tears. All laboratory tests
were normal including complete blood count, sedimenta-
tion rate, blood glucose, urea and creatinine levels, liver
functions, blood and urine cooper and ceruloplasmin
level, serum lipids and electrolytes and analysis of urine.
The mini-mental score was 27/30. The response to levo-
dopa therapy was poor.
K. Ba~i} Baronica et al.: Multiple System Atrophy, Coll. Antropol. 35 (2011) Suppl. 1: 287–292
289
Fig. 1. a) Mild to moderate brainstem and cerebellar atrophy in a patient with a clinical diagnosis of MSA with predominant Par-
kinsonism and cerebellar symptoms on T1 weighted sagittal sections on 1.5 T MR device (GE Signa 1.5 T Excite Scanner, General Elec-
tric Company, Milwaukee, WI, USA); b) Similar level of atrophy visible on T1 weighted sagittal sections on 3T MR device (Magnetom
3T Trio Tim Vision, Siemens, Erlangen, Germany).
a b
On initially performed 1.5T MRI, the most prominent
neurodegenerative feature of brain stem, cerebellum and
basal ganglia was atrophy (Figure 1a, b). Typical features
like slit-like hyperintense putaminal rim (Figure 2a, b),
»hot-cross bun sign« and MCP hyperintensities (Figure
3a and b) were detected in T2 weighted images and
FLAIR sequences only on higher resolution (3T) MRI de-
vice.
Patient was suggested to wear elastic compressive
stocking, to make postural changes and head-up tilt of
the bed at night. Liberal salt intake was recommended.
He was referred to speech-language therapist who started
speech therapy. Intense physical therapy was also started.
Discussion and Conclusion
Six months from the onset of the first symptoms our
patient has had both cerebellar and parkinsonian symp-
toms accompanied with signs of autonomic dysfunction.
However, orthostatic blood pressure decline did not meet
the level required for diagnosis of probable MSA so the
diagnosis of possible MSA was made. According to second
consensus statement on diagnosis of MSA, for making a
diagnosis of possible MSA in addition to Parkinsonism or
cerebellar syndrome, there must be one feature involving
autonomic dysfunction plus one other additional feature
that can include findings on history, clinical examination
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Fig. 2. a) axial T2 weighted section in patient on 1.5 T MR device shows normal posterolateral putaminal margin (GE Signa 1.5 T Ex-
cite Scanner, General Electric Company, Milwaukee, WI, USA); b) Mild slitlike hyperintensity of the posterolateral putaminal rim (arrow)
in same patient with diagnosis of possible MSA (Axial section, T2 weighting / Magnetom 3T Trio Tim Vision, Siemens, Erlangen, Ger-
many).
Fig. 3. a) Normal pons in patient on 1.5 T MR device (Axial section, T2 weighting / GE Signa 1.5 T Excite Scanner, General Electric
Company, Milwaukee, WI, USA) b) Cruciform degeneration of pontine fibers »Hot-cross bun« sign and predominant right middle cerebel-
lar peduncle hyperintensity (arrow) in same patient detected only on 3TMR device (Axial section, T2 weighting / Magnetom 3T Trio Tim
Vision, Siemens, Erlangen, Germany).
a b
a b
or changes in structural or functional imaging (Table 3)3.
MRI changes (Table 3) that can help diagnose possible
MSA-P and MSA-C include putaminal, pontine and mid-
dle cerebellar peduncle atrophy. T2-signal changes in-
cluding posterior putaminal hypointensity, hyperintense
lateral putaminal rim, »hot cross bun« sign and hyper-
intense MCP are also helpful3. All those MRI changes
should be visible on imaging using 1.5 T MR device ac-
cording to second consensus statement on diagnosis of
MSA3. In previous studies on MRI of MSA patients 1.5 T
MR devices were used for demonstration of those struc-
tural changes4,13,19 but our case showed that some of
those changes may not be visible on 1.5 T MRI device. Al-
though our patient already had both cerebellar and par-
kinsonian symptoms together with signs of involvement
of autonomic system so the criteria for diagnosis of possi-
ble MSA according to second consensus statement were
fulfilled, the 1.5 T MRI imaging did not demonstrate
some of typical findings for possible MSA3. »Hot cross
bun« sign, MCP hyperintensities and hyperintense slit
like putaminal rim were demonstrated only after using
3T MRI device. The most of other additional features re-
quired for making the diagnosis that are listed in Table 3,
are much more difficult to use. Confirmation of rapidly
progressive Parkinsonism, poor response to levodopa, de-
velopment of swallowing problems (dysphagia) or pos-
tural instability, require significant period of time (from
3 months to 5 years), while other functional studies like
SPECT or FDG-PET may be preformed only in well
equipped hospital centers. Additionally, using MRI in-
stead of PET or SPECT avoids radioactive exposure of
patients. Despite the fact that our patient already had
fulfilled criteria for diagnosis of possible MSA, imaging
on conventional 1.5 T MRI device did not demonstrate
some of structural changes as additional diagnostic fea-
tures that can help in establishing the diagnosis of possi-
ble MSA. Our case points to the assumption that if typi-
cal structural changes that can help in diagnostic process
of possible MSA are not clearly visible on routinely used
1.5 T MRI devices19, exams should be repeated on 3T
MRI device if feasible, in order to demonstrate findings
that are required for establishing the diagnosis of possi-
ble MSA.
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VA@NOST UPORABE MAGNETNE REZONANCIJE VISOKE REZOLUCIJE U DIJAGNOSTICI
MOGU]E MULTIPLE SISTEMNE ATROFIJE – PRIKAZ SLU^AJA
S A @ E T A K
Multipla sistemna atrofija (MSA) je sporadi~na, progresivna neurodegenerativna bolest klini~ki karakterizirana zna-
kovima autonomne disfunkcije, parkinsonizma (MSA-P) i cerebelarnim simptomima (MSA-C) u bilo kojoj kombinaciji.
Parkinsonizam je prisutan u ve}ine bolesnika (80%). U po~etku bolesti autonomna disfunkcija je izra`ena kod otprilike
40% bolesnika dok je kod 20% bolesnika dominantna cerebelarna simtomatologija1,2. Prema kriterijima za dijagnozu
MSA koje su postavili eksperti na drugoj konferenciji o dijagnostici MSA za dijagnozu mogu}e MSA uz postojanje parkin-
sonizma ili cerebelarnih simptoma moraju postojati i znaci autonomne disfunkcije i jedna od dodatnih karakteristika
koje uklju~uju anamnezu, klini~ki nalaz ili strukturne ili funkcionalne promjene verificirane slikovnim metodama3.
Prikazujemo {ezdesetgodi{njeg bolesnika sa parkinsonizmom, cerebelarnim simptomima i znacima zahva}anja auto-
nomnog `iv~anog sustava ~iji stupanj prema zadanim kriterijima nije dovoljan za dijagnozu vjerojatne MSA. Rezultati
laboratorijske obrade su bili unutar granica normale. Na inicijalno u~injenoj magnetnoj rezonanciji (MR) mozga vid-
ljiva je atrofija mo`danog debla, malog mozga i bazalnih ganglija. Promjene tipi~ne za MSA kao »hot-cross bun« znak,
hiperdenzni posterolateralni rub putamena i hiperdenzni srednji cerebelarni pedunkuli su bili detektirani kori{tenjem
MR aparata ja~ine 3 T4. Na{ slu~aj ukazuje na mogu}nost da se neke strukturalne promjene mozga koje mogu pomo}i u
dijagnozi mogu}e MSA ne moraju uvijek jasno prikazati kori{tenjem MR mozga ja~ine 1.5 T te stoga preporu~amo,
ukoliko je izvedivo, kori{tenje aparata ja~e rezolucije u svrhu prikaza karakteristika koje mogu pomo}i u postavljanju
dijagnoze mogu}e MSA.
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